This Month in Genetics  by Garber, Kathryn B.
EDITORS’ CORNER
This Month in Genetics
Kathryn B. Garber1,*APOL1 Variants Are Associated with Progression of
Kidney Disease
Although black and white populations have a fairly similar
prevalence of early-stage kidney disease, black patients are
at a much higher risk of end-stage disease. The discovery
that risk alleles in APOL1 are associated with end-stage kid-
ney disease was met with excitement, particularly given
the fact that these risk alleles are almost exclusively found
in African-derived populations. At what point is this gene
contributing to disease? A joint publication from two
studies (the African American Study of Kidney Disease
and Hypertension [AASK] and Chronic Renal Insufficiency
Cohort [CRIC] studies) addressed this from the view of
long-term progression of renal disease. Although disease
progression is most likely multifactorial, both cohorts
provide evidence that APOL1 variation is associated with
disease progression of chronic kidney disease. This effect
is independent of diabetes status and blood pressure con-
trol. Although not the full explanation, this work supports
the idea that variation in APOL1 partially explains racial
disparities in end-stage kidney disease.
Parsa et al. (2013). N. Engl. J. Med. 369, 2183–2196.
Three Randomized Trials of Pharmacogenetic Dosing
of Warfarin and Its Analogs
Vitamin K antagonists, such as warfarin, are ideal candi-
dates for pharmacogenetic testing because they are widely
prescribed anticoagulants and have a narrow therapeutic
window. This leaves patients who use these medications
at a risk of hemorrhage if the dose is too high or of clot-
ting-related events if the dose is too low. Several attempts
have been made to develop warfarin dosing algorithms
that incorporate genotype information, but their efficacy
has not been thoroughly documented. Three large ran-
domized prospective trials that aimed to settle this ques-
tion have just been published. Compared to a typical
clinical dosing algorithm, the pharmacogenetic algorithm
did not improve the time in the proper therapeutic range
(the primary endpoint) for warfarin or two related drugs.
The study by Pirmohamed et al. was the only trial that
showed some success and had assessed pharmacogeneti-
cally guided warfarin dosing in comparison to a fixed
dosing strategy, which is commonly used in certain
countries. As discussed in the accompanying editorial
by Bruce Furie (Furie [2013]. N. Engl. J. Med. 369, 2345–
2346.), these studies together provide little support for1Department of Human Genetics, Emory University School of Medicine, Atlan
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Ththe use of pharmacogenetic information in dosing these
medications.
Kimmel et al. (2013). N. Engl. J. Med. 369, 2283–2293.
Pirmohamed et al. (2013). N. Engl. J. Med. 369, 2294–2303.
Verhoef et al. (2013). N. Engl. J. Med. 369, 2304–2312.
The Essence of Maleness
Some researchers have warned that the Y chromosome
might be on its way to an evolutionary dead end. Although
accumulating data suggest that this is actually not the case,
how little of the Y is too little? Yamauchi et al. pushed
the boundaries of the Y chromosome in a recent study
to determine how little of the chromosome is needed to
produce offspring. Ultimately, two Y chromosome genes
were sufficient: Sry, which is critical for testis determina-
tion, and Eif2s3y, which encodes a spermatogonial prolif-
eration factor. Inmale mice lacking a Y chromosome, these
two genes were added back to the genomes in order to yield
some spermatogenesis. Although the germ cells produced
by these mice were found in low numbers and were not
fully developed, round, spermatid-like cells could be iso-
lated from testicular suspensions and used in intracyto-
plasmic sperm injection, resulting in morphologically
normal and fertile pups of the expected genotypes. The
success of this assisted reproduction was lower than what
one achieves with XY control mice, and this seemed to
be due to the fact that many of the spermatids from the
mice lacking a Y chromosome were actually diploid and
thus led to the production of triploid zygotes.
Yamauchi et al. (2013). Science. Published online November
21, 2013. http://dx.doi.org/10.1126/science.1242544.
One-Two Punch
In order for useful comparisons to be made, a genetic
knockout model should differ from its wild-type strain by
the loss of a single specific gene. In truth, because of either
random mutation or evolutionary forces, these strains
could acquire second site mutations that might confound
experimental results. To assess this potential diversifica-
tion, Teng et al. monitored substrain variability in many
different strains of the Saccharomyces cerevisiae knockout
collections. Unlike the wild-type, substrains of many indi-
vidual knockout strains could be revealed when the yeast
were put under heat or nutritional stress. Second site
mutations gave rise to this phenotypic variation and could
be segregated away from the original gene knockouts viata, GA 30322, USA
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tetrad analysis. Comparisons of many different strains
indicate that rather than simply resulting from random
mutation, the original knockout strains can yield parallel
and convergent evolution. First, independent knockouts
of the same gene often have secondary mutations in the
same locus. On the other hand, different knockout strains
can acquire second mutations in some of the same genes.
Overall, this work suggests that individual gene knockout
can drive genome evolution.
Teng et al. (2013). Mol. Cell 52, 485–494.
Setting Boundaries
In X chromosome inactivation, expression of the noncod-
ing transcript Xist is an initiating step that recruits
chromatin modifiers to one of the two X chromosomes
in female mammalian cells, thereby silencing gene expres-
sion. Not all genes on the inactive X are completely silent,
though, and these tend to be physically clustered together.
What defines the active and inactive boundaries on the4 The American Journal of Human Genetics 94, 3–4, January 2, 2014inactive X? Laura Carrel and colleagues tackled this by
using female mouse embryonic stem cells in which trans-
genes had been inserted into the X chromosome. The
transgenes included an X-linked gene (Kdm5c) that nor-
mally escapes X inactivation, as well as differing amounts
of downstream sequence. Despite their insertion in X chro-
mosome regions that are normally silent on the inactive X,
the Kdm5c transgene escaped inactivation in these cells
and must therefore have carried the sequences needed
for this escape. For some of the transgene insertions, genes
adjacent to the insertion were regulated normally. For
another, genes as far as 350 kb downstream of the trans-
gene insertion escaped X inactivation inappropriately.
This transgene insertion lacked sequences that are
normally downstream of Kdm5c, implying that within
those sequences resides an element that normally serves
as a boundary between the active and silent genes on the
inactive X chromosome.
Horvath et al. (2013). PLoS Genet. 9, e1003952.This Month in Our Sister JournalsDoes a Mutation, like Lightning, Strike Only Once?
As the old adage goes, lightning never strikes twice. Most
theoretical models for population genetics follow a similar
line of thinking in that they work under the assumption
that a site in the genome can be mutated only once to
generate diallelic sites. In fact, additional mutation at the
same site can occur and could lead to triallelic variation,
which is being increasingly recognized in large-scale data
sets. Ignoring the potential for these repeat mutations tooccur can be problematic, for example, when site fre-
quency spectra for variable sites are used for inferring
population histories. Jenkins et al. generated triallelic fre-
quency spectra and showed that they are more sensitive
to changes in the underlying population-growth models,
meaning that they might be better able to distinguish
between competing demographic models.
Jenkins et al. (2013). Genetics. Published online November 8,
2013. http://dx.doi.org/10.1534/genetics.113.158584.
